Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 2/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | PPM1B | O75688 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1053828 | 1.00 | NR1H2 (0.46) | NR1H2MEN1ALDH1A1KMT2ATSHR | |
| SCHEMBL3369192 | 1.00 | NR1H2 (0.46) | NR1H2MEN1ALDH1A1KMT2ATSHR | |
| Water SCHEMBL1055202 | 0.99 | NR1H2 (0.44) | NR1H2MEN1ALDH1A1KMT2ATSHR | |
| Water SCHEMBL1055969 | 0.99 | NR1H2 (0.44) | NR1H2MEN1ALDH1A1KMT2ATSHR | |
| SCHEMBL2930654 | 0.94 | NR1H2 (0.50) | NR1H2MEN1ALDH1A1KMT2ATSHR | |
| SCHEMBL2930651 | 0.94 | NR1H2 (0.50) | NR1H2MEN1ALDH1A1KMT2ATSHR | |
| SCHEMBL1052491 | 0.94 | NR1H2 (0.50) | NR1H2MEN1ALDH1A1KMT2ATSHR | |
| Furan SCHEMBL3838396 | 0.90 | NR1H2 (0.39) | NR1H2MEN1ALDH1A1KMT2ATSHR | |
| SCHEMBL15684099 | 0.89 | NR1H2 (0.43) | NR1H2MEN1ALDH1A1KMT2ATSHR | |
| SCHEMBL24555863 | 0.87 | NR1H2 (0.47) | NR1H2MEN1ALDH1A1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4171547-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Axial Therapeutics, Inc. (US) | 2023-05-03 | — | — | EP | disclosed |
| US-11358972-B2 | Pentacyclic heterocycles | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-14 | — | — | US | disclosed |
| US-11358972-B2 | Pentacyclic heterocycles | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-14 | — | — | US | disclosed |
| CN-113453762-A | Pentacyclic heterocyclic compounds | 卫材R&D管理有限公司 | 2021-09-28 | — | — | CN | disclosed |
| US-20200283452-A1 | PENTACYCLIC HETEROCYCLES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-09-10 | — | — | US | disclosed |
| US-20200283452-A1 | PENTACYCLIC HETEROCYCLES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-09-10 | — | — | US | disclosed |
| EP-2435037-B1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2014-11-12 | — | — | EP | disclosed |
| EP-2435037-B1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2014-11-12 | — | — | EP | disclosed |
| US-8497383-B2 | HIV protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-07-30 | — | — | US | disclosed |
| US-8497383-B2 | HIV protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-07-30 | — | — | US | disclosed |
| WO-2010138338-A1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-12-02 | — | — | WO | disclosed |
| EP-1863477-B1 | 3,4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | NOVARTIS AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| US-7807709-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-10-05 | — | — | US | disclosed |
| US-7807709-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-10-05 | — | — | US | disclosed |
| US-7550487-B2 | Pyrrolidine-3,4-dicarboxamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550487-B2 | Pyrrolidine-3,4-dicarboxamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20080194549-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | disclosed |
| US-20080194549-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | disclosed |
| EP-1863477-A1 | 3,4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | Novartis AG (CH) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006100036-A1 | 3, 4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | NOVARTIS AG (CH) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11358972-B2 | Pentacyclic heterocycles | CYP2C19, CYP2C18, XDH | NR1H2 458/4885MEN1 341/4885ALDH1A1 352/4885 |
| US-20200283452-A1 | PENTACYCLIC HETEROCYCLES | CYP2C19, CYP2C18, XDH | NR1H2 458/4885MEN1 341/4885ALDH1A1 352/4885 |
| US-20080194549-A1 | Organic Compounds | REN, ACE, OTC | NR1H2 2620/4885MEN1 2785/4885ALDH1A1 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.